Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | LXH 254 + Nazartinib |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| LXH 254 | LXH254|LXH-254|Naporafenib | BRAF Inhibitor 26 CRAF Inhibitor 12 | LXH 254 is a RAF inhibitor that selectively inhibits monomeric and dimerized BRAF and CRAF, which may lead to anti-tumor activity in RAF-mutant tumors and better tolerability (AACR Annual Meeting 2019, Abstract LB-114, PMID: 31059256). | |
| Nazartinib | EGF816|EGF-816 | EGFR Inhibitor 3rd gen 28 | Nazartinib (EGF816) is a third generation EGFR inhibitor with selectivity towards mutant forms of EGFR, resulting in inhibition of tumor cell growth (PMID: 27433829, PMID: 31954624). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03333343 | Phase I | LXH 254 + Nazartinib Nazartinib + Trametinib Gefitinib + Nazartinib Nazartinib + Ribociclib Capmatinib + Nazartinib | Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC | Active, not recruiting | ITA | DEU | CAN | 3 |